J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab's pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Numab), a clin ...

文章核心观点 - 公司最近一个交易日的股价下跌1.82%,低于标普500指数0.7%的涨幅[1] - 公司过去一个月的股价上涨1.96%,低于医疗行业3.27%和标普500指数4.03%的涨幅[2] - 公司即将发布的财报预计每股收益将下降2.5%,收入将下降12.38%[3] - 全年来看,公司每股收益和收入分别预计增长7.26%和下降5.1%[4] - 分析师对公司的预测有所下调,这反映了短期业务趋势的变化[5][6] - 公司目前的市盈率略高于行业平均水平,PEG比率也高于行业平均[8][9] - 公司所属的大型制药行业目前在所有行业中排名靠后[10][11]

In today’s uncertain market, securing investment returns is essential to protect your wealth from future downturns. Three businesses stand out as islands of stability amid geopolitical unrest and economic uncertainty. These massive companies in the industry provide defensive equities that are attractive buys for investors looking to strengthen their holdings. The first one shows substantial expansion in margins and profit growth. As a fundamental requirement, its diverse range of medical equipment and medic ...

NEW YORK — A group of cancer victims sued Johnson & Johnson JNJ.N on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company’s bankruptcy to resolve tens of thousands of lawsuits alleging its talc products contained asbestos and caused cancer. Five plaintiffs who seek to represent over 50,000 people who have sued J&J over its talc products filed the proposed class action in New Jersey federal court. 3 J&J has said that its baby powder and ...

Investors often look to safe-haven equities for stability and reliable returns during uncertain economic times. Here are seven strong afe-haven stocks to buy that offer encouraging chances to endure financial disasters. To begin with, the first has had notable growth in its markets, especially in the United States, due to its well- received product introductions and market penetration. The second one sustains its market leadership through effective operations and strong returns to shareholders while deliver ...

强生公司股息收入 - 强生公司是一家高质量的股息股票[1] - 强生公司已连续62年增加股息支付，属于股息王中的精英[1] - 强生公司的前瞻性股息收益率接近3.3%，是标普500指数基金的两倍[2] - 持有约202股强生公司股票才能获得1000美元的年度股息收入[3] - 需要投资约31,000美元才能收集1000美元的年度股息收入[3] 投资多样化 - 投资者应该持有至少25只股票的多样化投资组合[4] 强生公司财务状况 - 强生公司具有AAA信用评级，拥有充裕的现金资产和稳定增长的现金流[5] - 强生公司是寻求安全和稳健股息收入的理想股票[5]

Johnson & Johnson (JNJ) announced that it has entered into a definitive agreement to acquire private biotech Proteologix for $850 million in cash, with the potential for an additional milestone payment. The transaction is expected to be closed in mid-2024, subject to customary closing conditions. With the latest acquisition, JNJ is looking to boost its dermatology portfolio with an aim to address significant unmet needs in atopic dermatitis (AD), also known as eczema. Proteologix is engaged in developing bi ...

A month has gone by since the last earnings report for Johnson & Johnson (JNJ) . Shares have added about 5.5% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Johnson & Johnson due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q1 Earnings Beat Estimates, Sales Mis ...

业绩总结 - Johnson & Johnson在2023年第一季度增长6.5%，主要得益于业务竞争力的提升[51] - 公司计划在2025年初推出肩部和脊柱手术机器人[65] - 公司在心脏电生理学领域市场领先，预计将在2024年底获得FDA批准[84] 用户数据 - 在全球范围内，手术程序逐渐恢复正常，但仍然存在对创新产品的强劲需求[52] - 骨科领域仍然受到持续的支持，由于疫情期间缺乏护理导致的积压，预计至少在今年上半年仍将持续[54] - 在关节重建业务中，公司在膝关节方面表现出色，市场份额领先，全球第二[60] 未来展望 - Johnson & Johnson在2018年的医疗技术业务中，高增长市占率为20%，到2023年增长至50%[8] - 公司在心血管领域继续专注于提升Abiomed和Shockwave的业绩，未来可能考虑其他资产[48] - Johnson & Johnson在骨科业务中，通过减少产品种类20%，预计将在2026年至2027年期间提高利润率[34] 新产品和新技术研发 - 公司计划在2025年初推出肩部和脊柱手术机器人[65] - 公司在心脏电生理学领域市场领先，预计将在2024年底获得FDA批准[84] 市场扩张和并购 - 过去5年，Johnson & Johnson在M&A上投资超过220亿美元，目的是进入高增长领域，满足最重要的医疗需求[10] - Johnson & Johnson在心血管领域市场领先地位，通过收购Abiomed和Shockwave等公司，进一步扩大业务规模[26][28] - Johnson & Johnson的M&A策略主要关注战略、科学和财务方面，以满足特定需求并为公司和股东带来回报[39][40][41] 负面信息 - 无相关信息 其他新策略和有价值的信息 - 公司在心脏电生理学领域市场领先，预计将在2024年底获得FDA批准[84] - 公司计划在2025年初推出肩部和脊柱手术机器人[65]

业绩总结 - 上一年度管道成功率为90%，今年第一季度为85%[5] - DARZALEX成为最畅销产品，正在不断增长[13] - CARVYKTI在第二线获得批准，表现出色[22] 新产品和新技术研发 - 在多个领域取得成功，包括肿瘤学、免疫学和神经科学[5] - 在多发性骨髓瘤领域取得成功，推出TECVAYLI、TALVEY和CARVYKTI等产品[6] - 在前列腺癌领域取得成功，有四种新机制处于临床阶段[7] - 推出RYBREVANT，针对EGF受体突变肺癌的新标准治疗[8] - 在免疫学领域推出TREMFYA和SPRAVATO等产品[9] 市场扩张和并购 - J&J在CAR-T和细胞疗法方面具有战略优势[50] - TARIS收购后推出的药物-器械组合在临床试验中表现出83%的完全反应率[63] - 利用新技术制造的器械和靶向疗法，在临床中取得90%以上的完全反应率[64] - 新疗法在膀胱癌治疗中具有出色的耐受性和疗效，易于操作[67] 其他新策略和有价值的信息 - 早期膀胱癌治疗市场庞大，每年有60万新病例[62] - MARIPOSA研究显示lazertinib/RYBREVANT组合在前线治疗中表现出色，等待全球批准[79] - 新的药物治疗方案采用皮下注射，更方便且耐受性更好[81] - IL-23受体抑制剂2113在牛皮癣治疗中表现出色，吸引了大量患者参与临床试验[102] - J&J在创新方面有广泛的合作计划，包括与其他公司合作开发新技术和产品[113] - J&J在CAR-T领域进行了收购和合作，致力于优化CAR结构和自动化制造[114]